Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Crossover Study of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2013
Price :
$35
*
At a glance
- Drugs LY 2624803 (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- 05 Feb 2013 New trial record